Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
Takeda Pharmaceutical has a new U.S. biotech to add to its portfolio of drug developers. The pharma outfit announced this morning that it will buy out La Jolla, CA-based Intellikine and scoop up its
Infinity Pharmaceuticals, a 2005 Fierce 15 company, has scooped up the global development and commercialization rights to a portfolio of oral PI3K inhibitors developed by Intellikine, including one
La Jolla, CA-based startup Intellikine has quickly racked up 1,500 drug candidates that can influence the PI3 kinase pathway, an indication of the biotech company's intensity and a key reason it has
La Jolla, CA-based Intellikine has scooped up $51 million in venture fund commitments to support its work in one of the hottest fields in biomedical research. Novartis Bioventures led the financing